Image pharmaphorum Editor Oncology Beyond traditional cancer treatment: Can we confront unmet n... Surgery, chemotherapy, radiotherapy, and immunotherapy are designed to kill cancer, but what if we could control cancer? R&D The growth of radiotherapeutics: Addressing supply chain com... Players, current and emergent, should prepare for complexities in the supply chain as radiotherapeutics continues to rise. Sales & Marketing Sponsored Go slow to go fast: Setting a content transformation journey... Pharma marketing is evolving and it’s evolving quickly. How can organisations successfully ride the wave of this transformation? Digital Frontiers Health 2024: Day Two We are back for Day Two of Frontiers Health, coming to you live from the heart of Berlin! Load more results
Oncology Beyond traditional cancer treatment: Can we confront unmet n... Surgery, chemotherapy, radiotherapy, and immunotherapy are designed to kill cancer, but what if we could control cancer?
R&D The growth of radiotherapeutics: Addressing supply chain com... Players, current and emergent, should prepare for complexities in the supply chain as radiotherapeutics continues to rise.
Sales & Marketing Sponsored Go slow to go fast: Setting a content transformation journey... Pharma marketing is evolving and it’s evolving quickly. How can organisations successfully ride the wave of this transformation?
Digital Frontiers Health 2024: Day Two We are back for Day Two of Frontiers Health, coming to you live from the heart of Berlin!
News Gilead's twice-yearly PrEP drug is cleared by FDA Gilead has FDA approval for a twice-yearly PrEP drug, but could proposed cuts to US funding for HIV prevention programmes hinder its take-up?
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
